secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2025-06-04T23:59:59+00:00
Accession:  0001193125-25-134913
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics prices $100M common stock offering at $5.75 per share
------------------------------------------------------------------------

- Offering of 17.4M shares at $5.75/share; net proceeds ~$93.7M (~$107.8M if underwriters' option fully exercised).
- Underwriters granted 30-day option to purchase up to 2.61M additional shares at the same price.
- Proceeds to fund clinical development of Haduvio for chronic cough in IPF, non-IPF ILD, and RCC.
- Cash runway extended into 2029 based on current plans; additional capital needed for regulatory approval.
- Offering expected to close on June 5, 2025; Morgan Stanley, Leerink, Stifel, Cantor as joint book-runners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000119312525134913/0001193125-25-134913-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000119312525134913/d34558d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-134913

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer